Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 4091-4100 Newer>

Managed Care August 2007 John Carroll	Convenient Care Clinics Inconvenience the AMA The physician lobbying organization wants insurers to stop contributing to the growth of limited-care offices in chain stores.
Managed Care August 2007 Martin Sipkoff	Soaring Price of Cancer Drugs Leads Plans To New Approaches Insurers are trying different methods, from pay for performance to promoting preventive care, to hold down cost of chemotherapy drugs.
Managed Care August 2007	Compensation Monitor Psychiatrists are paid well by drugmakers.
Managed Care August 2007	Managed Care Outlook Specialty drugs increasingly used to treat chronic conditions.
CFO September 1, 2007 John Goff	Critical Condition Tenet Healthcare has been laid low by scandal, fraud, and cash-draining litigation. Can new CFO Biggs Porter help cure the ailing hospital operator?
CFO September 1, 2007 Lori Calabro	At Your Beck and Call Concierge plans offer the kind of health care Michael Moore would love -- if it were universal. But are they worth the out-of-pocket expense?
The Motley Fool August 31, 2007 Brian Orelli	A Stem-Cell Primer Public funding from states could help companies doing stem cell research. Read about Geron, StemCells, Osiris Therapeutics, ViaCell and Invitrogen, companies that may profit from the increased public spending.
The Motley Fool August 31, 2007 Brian Lawler	Novartis on the Biosimilar Attack Novartis received final marketing approval today for only the second biosimilar product ever to gain a regulatory OK in the European Union. The EU market welcomes the drugmaker's copy of a treatment for anemia.
The Motley Fool August 31, 2007 Brian Lawler	4 Biotech Bets Under $10 Development stage drugmakers are among the most exciting stocks to follow. Here are four that are all worth a place on your watch list: Pharmacopeia, Pain Therapeutics, Pharmasset, and SGX Pharmaceuticals.
The Motley Fool August 31, 2007 Brian Lawler	Tercica Triumphs With the FDA Swiping patients from competitors is a key part of Tercica's plan to make its hormone disorder treatment a success.
<Older 4091-4100 Newer> Return to current articles.